Compare TDF & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TDF | AKBA |
|---|---|---|
| Founded | 1994 | 2007 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.1M | 251.0M |
| IPO Year | N/A | 2014 |
| Metric | TDF | AKBA |
|---|---|---|
| Price | $10.89 | $1.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | 75.5K | ★ 6.4M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 93.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.95 | $0.82 |
| 52 Week High | $12.20 | $4.04 |
| Indicator | TDF | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 51.51 | 73.05 |
| Support Level | $10.33 | $1.32 |
| Resistance Level | $11.37 | $1.56 |
| Average True Range (ATR) | 0.25 | 0.09 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 75.65 | 88.37 |
Templeton Dragon Fund Inc is a closed-end management investment company. The fund seeks long-term capital appreciation by investing majority of its total assets in equity securities of China companies. It invest in various sectors such as gas & consumable fuels, auto components, banks, beverages, communications equipment, healthcare equipment & supplies, restaurants & leisure, household durables and many others.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.